Celularity announced that it presented in vivo data from its T-cell therapy platform at this year’s ASCO Annual Meeting in Chicago. These data show that PT-CD16VS, Celularity’s T-Cell preclinical asset, has potent in vitro and in vivo activity and has the potential to be combined with various monoclonal antibodies to target multiple cancers. Please find the link to the abstract here. Celularity has adopted a “universal receptor” approach to develop a platform of genetically modified T-cells expressing a proprietary CD16 to be combined with various approved antibodies to address multiple cancers and other conditions. Data demonstrating PT-CD16VSs activity in combination with trastuzumab against HER2-positive cancers has already been presented at AACR in April. These data further build on this to demonstrate much broader potential across multiple hematological and solid tumors. “These important data further demonstrate the potential of combining Celularity’s placental-derived cell therapy platform with currently available antibody therapies to address difficult-to-treat cancers and avoid some of the challenges of traditional cell therapy, including antigen escape and tolerability,” said Dr. Robert Hariri, Celularity’s CEO and Founder. “We are also continuing to advance our pipeline to address aging-related healthcare challenges beyond cancer including cellular senescence. This work highlights the deep expertise and capabilities in cell therapy resident at Celularity and our ability to modify and engineer those cells in our state-of-the-art manufacturing facility.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELU:
- Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Celularity receives noncompliance notification from Nasdaq
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
- Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
- Celularity announces publication on benefits of placental circulating T cells